Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

Nature Medicine

Volumn 2, Issue 9, 1996, Pages 979-984

  Begent, R H J ^a   Verhaar, M J ^a   Chester, K A ^a   Casey, J L ^a   Green, A J ^a   Napier, M P ^a   Hope Stone, L D ^a   Cushen, N ^a   Keep, P A ^a   Johnson, C J ^a   Hawkins, R E ^b   Hilson, A J W ^a   Robson, L ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Centre for Protein Engineering   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY MFE 23; BACTERIUM ANTIBODY; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; FV ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACTERIOPHAGE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

BACTERIA (MICROORGANISMS); FILAMENTOUS BACTERIOPHAGE;

EID: 9544250404     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0996-979     Document Type: Article

References (33)

1. Chester, K.A. & Hawkins, R.E. Clinical issues in antibody design. Trends Biotechnol. 13, 294-300 (1995)
2. Yokota, T , Milenic, D.E., Whitlow, M. & Schlom, J. Rapid tumour penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52, 3402-3408 (1992).
3. Huston, J.S. et al. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85, 5879-5883 (1988).
4. Colcher, D. et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. Cancer Inst. 82, 1191-1197 (1990).
5. Milenic, D.E. et al Construction, binding properties, metabolism, and tumor targeting of a single chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 51, 6363-6371 (1991).
6. Savage, P. et al. Construction, characterisation and kinetics of a single chain antibody recognising the tumour associated antigen placental alkaline phosphatase. Br. J. Cancer 68, 738-742 (1993).
7. Huse, W.E. et al. Generation of a large combinatorial library of the immunological repertoire in phage lambda. Science 246, 1275-1281 (1989)
8. McCafferty, J., Griffiths, A.D., Winter, G. & Chiswell, D J. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 348, 552-554 (1990).
9. Clackson, T., Hoogenboom, H.R., Griffiths, A.D. & Winter, G. Making antibody fragments using phage display libraries. Nature 352, 624-628 (1991).
10. Hawkins, R.E., Russell, S.J. & Winter, G. Selection of phage antibodies by binding affinity: Mimicking affinity maturation. J. Mol. Biol. 226, 889-896 (1992).
11. Chester, K.A. et al. Phage libraries for generation of clinically useful antibodies. Lancet 343, 455-456 (1994).
12. Griffiths, A D. et al Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13, 3245-3260 (1994).
13. Verhaar, M.J et al. A single chain Fv derived from a filamentous phage library has distinct tumour targeting advantages over one derived from a hybridoma. Int. J. Cancer 61, 497-501 (1995).
14. Casey, J.L. et al. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J Immunol. Methods 179, 105-116 (1995).
15. Operation Manual. Cancer Research Campaign operation manual for control of production, preclinical toxicology and phase I trials of anti tumour antibodies and drug antibody conjugates. Br. J. Cancer 54, 557-568 (1986).
16. Houghten, R.A et al. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature 354, 84-86 (1991).
17. Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249, 505-510 (1990).
18. Bunin, B A , Plunkett, M.J. & Ellman, J A. The combinatorial synthesis and chemical and biological evaluation of a 1,4-benzodiazepine library. Proc. Natl. Acad. Sci. USA 91, 4708-4712 (1994).
19. 131I distribution by gamma camera imaging . Eur. J. Nucl. Med. 16, 361-365 (1990).
20. 2 antibodies. Br. J. Cancer 70, 521-525 (1994).
21. Begent, R.H.J. et al. Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br. J. Cancer 60, 406-412 (1989).
22. Takakura, Y., Fujita, T , Hashido, M. & Sezoni, H. Disposition characteristics of macromolecules in tumour-bearing mice. Pharm. Res. 7, 339-346 (1990).
23. 2::anti-CEA scFv fusion protein. Immunotechnology 2, 47-57 (1996).
24. Bagshawe, K.D., Sharma, S.K., Springer, C.S. & Antoniw, P Antibody directed enzyme prodrug therapy: Pilot scale clinical trial. Tumour Target 1, 17-29 (1995).
25. Yang, W-P et al. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV antibody into the picomolar range. J. Mol. Biol. 254, 392-403 (1995).
26. Barbas, C.F. III. Synthetic human antibodies Nature Med 1, 837-839 (1995).
27. 2 J Immunol Methods 158, 49-56 (1993).
28. Moertel, C.G. Chemotherapy for colorectal cancer. N. Engl. J. Med. 330, 1136-1142 (1994)
29. Glimelius, B. for the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial Eur J. Cancer S82 (Suppl. 2), 462 (1991).
30. 99TTc radiolabelling using a phage-derived single chain Fv with C- terminal cysteine for colorectal tumour imaging J. Nucl. Med. 37, 868-872 (1996).
31. Begent, R.H.J et al. Cancer Research Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials Eur. J. Cancer 29A, 1907-1910 (1993).
32. Hunter, W.M. & Greenwood, F.C Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194, 495-496 (1962).
33. Ledermann, J.A et al. A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int. J. Cancer 47, 659-664 (1991).